A library of peptide research, organized by hub.
Five subject hubs: peptide science fundamentals, analytical quality, evidence standards, compound profiles by pathway, and regulatory science. Every article separates molecule-level evidence from product-level status.
Five subject hubs.
Peptide Science Fundamentals
How peptides are built, how they fold, how they signal, and why precise molecular identity is the foundation of every interpretable experiment.
Open hubAnalytical Quality and Testing
HPLC, mass spectrometry, content versus vial mass, counterions, residual solvents, water content, endotoxin and sterility, certificates of analysis, and blend testing.
Open hubEvidence and Research Literacy
Reading studies critically: the evidence ladder, reproducibility, sample size, statistical significance, sponsor funding, negative studies, and investigational status.
Open hubCompound Research Profiles
Pathway-organized reviews of incretin and metabolic receptors, hypothalamic and pituitary signaling, mitochondrial peptides, cellular senescence, neuroendocrine peptides, innate immune peptides, and matrix biology.
Open hubRegulatory and Responsible Research
RUO status, intended use, compounding, FDA peptide guidance, approved active versus approved product, peptide impurities, 503A evaluation, and responsible communication.
Open hubTopic index.
Fundamentals
Foundational concepts: what peptides are, how they differ from proteins and small molecules, and why precision matters.
Open sectionStructure
Sequence, conformation, modifications, and stereochemistry as determinants of biological activity.
Open sectionPharmacology
Receptor pharmacology, signaling pathways, and how peptide effects are characterized in research models.
Open sectionPharmacokinetics
Absorption, distribution, metabolism, exposure profiles, and engineered half-life extension.
Open sectionDesign
How peptide molecules are designed, modified, and engineered for stability and selectivity.
Open sectionAnalytical
Methods for identity confirmation, purity assessment, and content determination.
Open sectionQuality
Manufacturing controls, lot-level documentation, and supplier evaluation.
Open sectionReproducibility
Why findings replicate or fail, with attention to material, method, and reporting.
Open sectionEvidence Literacy
Reading studies critically across cell, animal, and human research.
Open sectionStatistics
Quantitative reasoning, effect sizes, confidence intervals, and common pitfalls.
Open sectionDiscovery & Development
Drug discovery, AI-driven design, manufacturing, and the path from molecule to candidate.
Open sectionRegulatory
FDA pathways, labeling concepts, and how research-use status differs from approval.
Open sectionRegulatory Science
Compounding regulation, intended-use doctrine, advisory committees, and editorial frameworks.
Open sectionField Outlook
Where peptide research is heading and which questions remain unsettled.
Open sectionComparative Science
Side-by-side comparisons across receptors, classes, routes, and product categories.
Open sectionEmerging Trends
Frontier areas: mitochondrial-derived peptides, senolytics, AMPs, BBB shuttles, oncology, and rare-disease research.
Open sectionResearch Practice
Laboratory operations: chain of custody, storage, COA evaluation, and supplier qualification.
Open sectionCompound Research
Compound-by-compound reviews of evidence, mechanism, safety, and product identity.
Open sectionFundamentals
Foundational concepts: what peptides are, how they differ from proteins and small molecules, and why precision matters.
Why Peptide Structure Matters: Sequence, Conformation, and Biological Activity
Even a single amino-acid substitution can change receptor affinity, stability, selectivity, or degradation. Peptide structure is not a footnote, it is the foundation of the experiment.
Read articleWhat Makes a Peptide Different From a Protein or Small Molecule?
Peptides occupy a distinct scientific space between traditional small molecules and larger proteins. Understanding that distinction is essential for interpreting research, evaluating material identity, and designing reproducible experiments.
Read articleStructure
Sequence, conformation, modifications, and stereochemistry as determinants of biological activity.
Pharmacology
Receptor pharmacology, signaling pathways, and how peptide effects are characterized in research models.
Pharmacokinetics
Absorption, distribution, metabolism, exposure profiles, and engineered half-life extension.
Design
How peptide molecules are designed, modified, and engineered for stability and selectivity.
Why D-Amino Acids and Retro-Inverso Design Matter
D-amino acids can make peptides more resistant to enzymatic degradation, but greater stability does not guarantee preserved biological function.
Read articleWhat Is a Peptide Analogue?
A peptide analogue is related to an endogenous or reference peptide, but structural changes may create new pharmacology, stability, and research limitations.
Read articleAnalytical
Methods for identity confirmation, purity assessment, and content determination.
Why Blend Testing Is Harder Than Single-Compound Testing
A blend is not validated merely because each component has been tested separately. The combined material creates new analytical and stability questions.
Read articleResidual Solvents in Synthetic Peptide Materials
Peptide synthesis and purification can involve multiple organic solvents, and trace residues require analytical methods designed specifically to detect them.
Read articleMass Spectrometry and Peptide Identity Confirmation
Mass spectrometry can provide powerful evidence of peptide identity, especially when combined with chromatographic separation and sequence-aware interpretation.
Read articleHPLC for Peptide Analysis: What It Can and Cannot Prove
HPLC is one of the most useful tools in peptide quality control, but a chromatogram must be interpreted within the limits of the method.
Read articleQuality
Manufacturing controls, lot-level documentation, and supplier evaluation.
What a Lot-Specific Certificate of Analysis Should Contain
A useful certificate of analysis should connect a defined material and a specific lot to transparent test methods, results, specifications, and responsible review.
Read articleEndotoxin, Bioburden, and Sterility: Three Different Questions
Endotoxin, bioburden, and sterility are often discussed together, but they measure different hazards using different methods.
Read articleWater Content and Lyophilized Peptide Stability
Lyophilization reduces water but does not guarantee a completely dry material. Residual moisture can influence both stability and measured mass.
Read articleWhy Counterions Matter in Peptide Research Materials
Counterions are easy to overlook because they are not part of the amino-acid sequence, yet they can materially affect the chemical form of a peptide preparation.
Read articlePeptide Content vs Gross Vial Mass
A vial labeled with a nominal mass may contain more than the peptide itself. Understanding that distinction is essential for reproducible quantitative research.
Read articleWhy 99% Purity Does Not Tell the Whole Story
A high purity number may look definitive, but it does not by itself prove molecular identity, actual peptide content, sterility, or suitability for a particular experiment.
Read articleWhy Peptides Aggregate, and Why Researchers Should Care
Aggregation is not merely a cosmetic problem. It can change the effective concentration, biological behavior, analytical profile, and safety interpretation of a peptide material.
Read articlePeptide Stability: What Happens Between Synthesis and the Experiment?
A peptide can be correctly synthesized and still change before the experiment through oxidation, deamidation, hydrolysis, adsorption, or aggregation.
Read articleReproducibility
Why findings replicate or fail, with attention to material, method, and reporting.
Evidence Literacy
Reading studies critically across cell, animal, and human research.
How to Build an Evidence Map for a Research Compound
An evidence map shows not only how much research exists, but what kind of research exists, where it agrees, and where uncertainty remains.
Read articleWhy Negative Peptide Studies Matter
Science becomes distorted when only positive peptide findings are visible. Negative and inconclusive studies are essential parts of the evidence base.
Read articleHow Sponsor Funding Should Be Interpreted in Peptide Trials
Funding source should be disclosed and examined, not used as an automatic reason to accept or reject a peptide study.
Read articleWhy Mechanism of Action Is Not the Same as a Proven Outcome
Mechanistic explanations are persuasive because they sound complete. In reality, a pathway can be real while the predicted outcome remains unproven.
Read articleIn Vitro, Animal, and Human Evidence Are Not Interchangeable
Every evidence model contributes something different. Treating cellular, animal, and human findings as equivalent is one of the fastest ways to overstate peptide research.
Read articleHow to Read a Peptide Study Without Overstating the Findings
Peptide studies can look persuasive while answering a much narrower question than the headline suggests. This guide shows how to evaluate the actual strength and scope of a finding.
Read articleStatistics
Quantitative reasoning, effect sizes, confidence intervals, and common pitfalls.
Statistical Significance vs Biological Significance in Peptide Research
Statistical significance asks whether data are difficult to reconcile with a null model. Biological significance asks whether the size and nature of the effect actually matter.
Read articleHow Small Sample Sizes Distort Peptide Research
A dramatic result in a small peptide study may reflect a real effect, random variation, or selective emphasis. Sample size determines how confidently those possibilities can be separated.
Read articleDiscovery & Development
Drug discovery, AI-driven design, manufacturing, and the path from molecule to candidate.
AI-Designed Peptides and the New Research Bottleneck: Validation, Testing, and Reproducibility
AI can generate peptide candidates faster than traditional discovery workflows, but speed creates a new bottleneck: validation. This article explains why identity confirmation, purity testing, biological assays, reproducibility, and evidence mapping become even more important as AI expands the candidate pipeline.
Read articleFrom Literature Review to Candidate Selection: How LLMs Are Changing Biomedical Research
Large language models are changing the front end of biomedical research. By organizing literature, extracting patterns, and supporting hypothesis generation, LLMs may help researchers move from scattered evidence to testable candidate lists faster than traditional workflows.
Read articleAI in Peptide Research: How LLMs and Generative Models Are Accelerating Discovery
Artificial intelligence is changing how researchers identify targets, design peptide sequences, and prioritize experiments. This article examines where AI is already accelerating peptide research, where the technology remains limited, and why experimental validation still determines scientific value.
Read articleGreen Chemistry and the Future of Peptide Manufacturing
Peptide synthesis can consume large volumes of solvents and reagents. Green chemistry seeks to reduce that burden without compromising identity or quality.
Read articlePeptide Manufacturing: From Solid-Phase Synthesis to Purification
Peptide manufacturing is a sequence of chemical reactions and separations. Every stage can create impurities that must be understood and controlled.
Read articleWhy Cyclization Can Improve Peptide Drug Properties
Cyclization constrains peptide structure and can improve stability or affinity, but the outcome depends on ring size, linkage, sequence, and target.
Read articlePeptide-Drug Conjugates: A Growing Research Frontier
Peptide-drug conjugates use a peptide as a targeting, transport, or biological component linked to a separate payload. Their performance depends on the entire construct.
Read articleLong-Acting Peptide Formulations: How Researchers Extend Exposure
Long-acting peptide design uses chemistry and formulation to slow degradation or clearance, but each strategy creates a distinct molecular and analytical profile.
Read articleThe Science of Oral Peptide Delivery
An oral dosage form does not prove oral bioavailability. Peptides must survive the gastrointestinal environment and cross several biological barriers.
Read articleWhy Peptide Delivery Remains a Major Scientific Challenge
Peptides can be potent and selective, yet delivery often determines whether that pharmacology can be translated into useful exposure.
Read articleFrom Lead Peptide to Clinical Candidate
A peptide becomes a clinical candidate only after chemistry, pharmacology, manufacturing, and safety evidence converge around a defined material.
Read articleAI-Driven Peptide Design: Promise, Limits, and Validation
AI can search peptide sequence space faster than conventional methods, but prediction quality depends on data quality, model assumptions, and rigorous wet-lab validation.
Read articleHow Peptide Drugs Are Discovered
Peptide discovery is not a single technique. It is a sequence of hypothesis generation, screening, molecular optimization, analytical confirmation, and experimental validation.
Read articleRegulatory
FDA pathways, labeling concepts, and how research-use status differs from approval.
Regulatory Science
Compounding regulation, intended-use doctrine, advisory committees, and editorial frameworks.
How to Write Responsible Scientific Product Content
Responsible scientific content explains identity, mechanism, evidence, limitations, and status without converting early research into a consumer promise.
Read articleWhy Laboratory Research and Human Administration Must Stay Separate
A reagent can support a valid experiment without being suitable for administration. Human use requires a different evidence, quality, oversight, and consent framework.
Read articleWhat FDA's 2026 Compounding Advisory Agenda Signals for Several Research Peptides
An advisory-committee agenda signals active regulatory evaluation. It is neither an approval nor a final prohibition, and the outcome must be reported after the meeting.
Read articleThe 503A Bulks List and Why Researchers Should Follow It
The 503A bulks process addresses whether certain substances may qualify for pharmacy compounding under defined conditions. It does not approve them as drugs.
Read articleWhy Peptide-Related Impurities Receive Regulatory Attention
Peptide impurities may differ from the intended sequence by only one residue or modification while retaining biological or immune activity.
Read articleThe Difference Between an Approved Active Ingredient and an Approved Product
A molecule can appear in an approved medicine while another product containing a similarly named ingredient remains unapproved, non-equivalent, or poorly characterized.
Read articleWhy Compounded Drugs Are Not FDA-Approved Drugs
Compounding can serve legitimate patient needs under defined legal conditions, but compounded products do not undergo FDA premarket approval.
Read articleWhat FDA's Peptide Clinical Pharmacology Guidance Means for Researchers
FDA's peptide guidance shows how many variables must be understood before peptide evidence can support a development program.
Read articleHow FDA Evaluates Intended Use for Online Research Products
FDA can infer intended use from the full commercial record, including what a company says, shows, bundles, links, and encourages customers to do.
Read articleResearch Use Only Does Not Mean Regulation-Free
Research-use language is one fact in a broader regulatory analysis. Regulators evaluate the product, claims, audience, accessories, and commercial context together.
Read articleField Outlook
Where peptide research is heading and which questions remain unsettled.
Comparative Science
Side-by-side comparisons across receptors, classes, routes, and product categories.
Approved Peptide Drugs vs Experimental Research Peptides
An approval validates a defined product, not every material containing a similar active ingredient.
Read articleTopical Peptide Evidence vs Systemic Peptide Claims
Route-specific discipline prevents topical findings from becoming unsupported systemic claims.
Read articleSingle-Compound Research vs Multi-Peptide Blends
Component literature is background, not validation. Blend-specific testing and evidence are required.
Read articleEndogenous Peptides vs Synthetic Analogues
Similarity to a natural peptide is context, not proof of equivalence.
Read articleGHRH Analogues vs Ghrelin-Receptor Agonists
Two upstream routes to growth-hormone release that should not be treated as interchangeable.
Read articleGLP-1, Dual Agonists, and Triple Agonists: A Receptor-Level Comparison
More receptor targets can mean broader effects, broader hypotheses, and broader uncertainty.
Read articleEmerging Trends
Frontier areas: mitochondrial-derived peptides, senolytics, AMPs, BBB shuttles, oncology, and rare-disease research.
Can Peptides Cross the Blood-Brain Barrier?
Cell penetration is not brain penetration. The correct question is how much intact material reaches which compartment.
Read articlePeptide Immunogenicity: Why Small Molecules Can Still Trigger Immune Responses
Small peptide should never be used as shorthand for non-immunogenic.
Read articleWhat the 2025 FDA Peptide Approval Landscape Tells Us
Modern peptide programs solve delivery and quality, not just receptor potency.
Read articlePeptide Therapeutics in Rare Disease Research
Rare-disease peptide research is a model of precision: clear biology, tightly defined materials, focused evidence.
Read articlePeptides in Oncology: Targeting, Imaging, and Delivery
Precision tools whose value depends on target validation, delivery, and product characterization.
Read articlePeptide Vaccines and Targeted Delivery Platforms
Platforms make peptides part of a multicomponent system whose performance depends on every linkage.
Read articleAntimicrobial Peptides and the Challenge of Therapeutic Selectivity
Selectivity, not raw antimicrobial potency, is the primary endpoint for serious AMP research.
Read articleSenolytic Peptides: What the Field Is Actually Testing
Selective biology, not marketing language, is the field's most important question.
Read articleThe Rise of Mitochondrial-Derived Peptides
Endogenous biology, biomarker studies, and synthetic administration must remain clearly separated.
Read articleResearch Practice
Laboratory operations: chain of custody, storage, COA evaluation, and supplier qualification.
How to Evaluate a Peptide Supplier's Certificate of Analysis
A polished certificate cannot replace audit history, change control, and consistent performance across lots.
Read articleHow to Store Research Peptides Responsibly
Storage requirements are material specific. Lyophilized does not mean indestructible.
Read articleHow to Document Peptide Chain of Custody
Chain of custody is part of reproducibility, not paperwork. Material history must survive delivery.
Read articleCompound Research
Compound-by-compound reviews of evidence, mechanism, safety, and product identity.
Selank Research Update (2026): Human Evidence, Anxiolytic Research, and Regulatory Status
Selank is a synthetic tuftsin-derived peptide that has been investigated primarily in neurobiology and anxiety research. This review examines published evidence, separates mechanistic findings from clinical data, and summarizes the current regulatory landscape.
Read articlePT-141 (Bremelanotide) Research Update (2026): Human Evidence, Melanocortin Biology, and Regulatory Status
PT-141, also known as bremelanotide, is unusual among peptide therapeutics because it progressed from experimental melanocortin research to FDA approval for a specific clinical indication. This review distinguishes established evidence from ongoing investigation while examining the broader melanocortin research landscape.
Read articleMelanotan II Research Update (2026): Human Evidence, Melanocortin Biology, and Regulatory Status
Melanotan II is a synthetic melanocortin peptide that has been studied for pigmentation, melanocortin receptor biology, and related physiological pathways. This review examines published human, animal, and laboratory evidence while separating mechanistic findings from clinical conclusions.
Read articleThymosin Alpha-1 Research Update (2026): Human Clinical Evidence, Immunology, and Regulatory Status
Thymosin Alpha-1 is one of the most extensively studied immunomodulatory peptides in clinical medicine. Unlike many investigational peptides, it has decades of human research and regulatory approvals in several countries. This review examines the evidence hierarchy, distinguishes approved uses from investigational research, and summarizes where the science stands in 2026.
Read articleIpamorelin Research Update (2026): Human Evidence, Ghrelin Receptor Biology, and Regulatory Status
Ipamorelin is a selective growth hormone secretagogue investigated for its effects on endogenous growth hormone signaling. This review examines the current evidence, separates mechanistic biology from clinical data, and summarizes its regulatory status as of 2026.
Read articleEpitalon Research Update (2026): Telomeres, Longevity Science, and the Human Evidence Gap
Epitalon has become one of the most discussed peptides in longevity research due to its reported effects on telomerase and cellular aging pathways. This review examines the current evidence, separates mechanistic findings from clinical data, and evaluates where the science stands in 2026.
Read articleKPV Research Update (2026): Human Evidence, Anti-Inflammatory Mechanisms, and Regulatory Status
KPV is a tripeptide derived from alpha-melanocyte-stimulating hormone that has attracted attention for its anti-inflammatory properties in experimental systems. This review examines current evidence, distinguishes mechanistic findings from human data, and summarizes the peptide's regulatory status as of 2026.
Read articleBPC-157 Research Update (2026): Human Evidence, Preclinical Data, and Regulatory Status
BPC-157 remains one of the most discussed experimental peptides in regenerative research, yet human evidence remains extremely limited. This review separates mechanistic promise from clinical evidence and examines where the science and regulation stand in 2026.
Read articleSNAP-8 and SNARE-Complex-Inspired Cosmetic Peptide Research
A mechanistic inspiration is not the same as equivalent target engagement or clinical performance.
Read articleL-Carnitine and the Mitochondrial Carnitine Shuttle
Established deficiency-related evidence does not generalize to every carnitine product or research question.
Read articleGlutathione Research: Redox Biology, Formulation, and Route Dependence
Reduced and oxidized glutathione, plus route and formulation, all change what a study can support.
Read articleNAD+ Research: Cofactor Biology vs Direct Administration Claims
Essential cofactor biology does not automatically validate every method of administering NAD+.
Read articleSLU-PP-332 Is Not a Peptide: ERR Agonism and Exercise-Mimetic Research
SLU-PP-332 should not be marketed as a peptide and exercise-mimetic language should be read as research shorthand.
Read article5-Amino-1MQ Is Not a Peptide: NNMT Inhibition and Preclinical Metabolic Research
Correctly classifying 5-Amino-1MQ as a small-molecule NNMT inhibitor is the first step toward responsible interpretation.
Read articleThymalin and the Problem of Poorly Defined Peptide Mixtures
Thymalin illustrates why a product name without composition data cannot inherit older literature.
Read articleTB-500 vs Thymosin Beta-4: Why the Names Cannot Be Used Interchangeably
TB-500 and thymosin beta-4 are routinely conflated, but only one has a confirmed sequence and a real literature base.
Read articleThymosin Alpha-1 and Immune Signaling Research
A chemically defined 28-amino-acid peptide with indication-specific evidence and jurisdictionally variable status.
Read articleLL-37 and the Dual Nature of Antimicrobial Peptide Signaling
LL-37 is a context-dependent host-defense peptide whose antimicrobial and inflammatory behaviors are tightly linked.
Read articleGHK-Cu: Copper Binding, Matrix Biology, and Route-Specific Evidence
GHK-Cu has a defined copper-binding chemistry and a route-specific evidence base that should not be merged into a single narrative.
Read articleDSIP Research: A Historical Peptide With an Uncertain Target
DSIP has accumulated decades of scattered findings without a validated receptor or reproducible clinical role.
Read articleSemax Research: Neurotrophic Signaling, Regional Literature, and Unanswered Questions
Semax is an ACTH-fragment analogue studied in neuroprotection and neurotrophic signaling, with a literature base that remains regionally concentrated and difficult to generalize.
Read articleSelank Research and the Difficulty of Validating Neurobehavioral Peptides
Selank is a tuftsin-derived peptide studied in stress, behavior, immune signaling, and gene expression, but independent validation remains limited.
Read articleEpitalon Research: Telomeres, Circadian Biology, and Evidence Gaps
Epitalon is a synthetic tetrapeptide associated with telomere, pineal, circadian, and aging claims, but the evidence base is limited and difficult to validate independently.
Read articleFOXO4-DRI and the Experimental Biology of Cellular Senescence
FOXO4-DRI is an experimental retro-inverso peptide designed to disrupt a protein interaction in senescent cells.
Read articleMOTS-c and Mitochondrial-to-Nuclear Signaling
MOTS-c is a mitochondrial-derived peptide studied as a signal connecting cellular stress, metabolism, and nuclear gene regulation.
Read articleMelanotan II: Broad Melanocortin Activity and Significant Safety Questions
Melanotan II is a nonselective melanocortin agonist whose broad receptor activity and unapproved marketplace use raise significant safety concerns.
Read articleBremelanotide and Central Melanocortin Signaling
Bremelanotide is a cyclic melanocortin receptor agonist with an FDA-approved product for a specific indication and a defined safety profile.
Read articleOxytocin Research Beyond the Headlines
Oxytocin has established reproductive physiology and approved obstetric use, but behavioral findings are more heterogeneous than popular summaries suggest.
Read articleKisspeptin and the Control of Reproductive Neuroendocrine Signaling
Kisspeptin is a central regulator of the hypothalamic-pituitary-gonadal axis and has meaningful human experimental evidence.
Read articleIGF-1 LR3 and the Challenge of Translating Growth-Signaling Research
IGF-1 LR3 is a modified analogue used in experimental systems, but approved recombinant IGF-1 evidence cannot be transferred to it automatically.
Read articleTesamorelin: A Defined GHRH Analogue With Established Human Research
Tesamorelin is a stabilized GHRH analogue with an FDA-approved finished product and a substantial human evidence base for a specific indication.
Read articleSermorelin and the Biology of GHRH(1-29)
Sermorelin is a synthetic version of the biologically active N-terminal segment of growth-hormone-releasing hormone.
Read articleIpamorelin and Ghrelin-Receptor Research
Ipamorelin is a synthetic growth-hormone secretagogue studied for agonism of the ghrelin receptor and stimulation of pituitary growth-hormone release.
Read articleCJC-1295, Mod GRF(1-29), and Why Product Identity Matters
CJC-1295 without DAC is often used as a marketplace label for chemically different materials, making sequence verification essential.
Read articleAOD-9604: From Growth-Hormone Fragment to Uncertain Research Candidate
AOD-9604 was designed from a growth-hormone fragment to investigate metabolic signaling without the full profile of intact growth hormone.
Read articleBPC-157 Research: What the Evidence Actually Shows
BPC-157 has a broad preclinical literature, but the gap between animal findings and credible human evidence remains substantial.
Read articleAmylin Biology and the Research Rationale for Cagrilintide
Cagrilintide is a long-acting amylin analogue developed to investigate satiety, gastric signaling, and combination pharmacology with incretin agents.
Read articleTriple-Receptor Agonism: What Retatrutide Research Is Testing
Retatrutide research asks whether one molecule can integrate GIP, GLP-1, and glucagon receptor signaling while maintaining an acceptable safety profile.
Read articleDual GIP/GLP-1 Receptor Agonism: The Science Behind Tirzepatide
Tirzepatide integrates GIP and GLP-1 receptor activity in one engineered peptide, creating a distinct pharmacologic profile rather than a simple stronger GLP-1 signal.
Read articleHow GLP-1 Receptor Agonism Is Studied in Metabolic Research
GLP-1 research spans receptor pharmacology, glucose-dependent endocrine signaling, gastric motility, central appetite pathways, and long-term clinical outcomes.
Read article